IL17A and myeloid sarcoma: We show that pretreating MSCs with IL-10 does reduce the proportion of IL-17–positive or GM-CSF–positive cells (Figure 7, A and B), indicating another potential approach to reducing the proinflammatory potential of MSCs from patients with MS.